Myelodysplastic syndrome/Acute myeloid leukemia
Conditions
Interventions
case series:Decitabine: 10 mg Subcutaneous injection one time/day, consecutively 5 days in a month x 12 times or three months until the MRD becomes negative
Sponsors
The First Affiliated Hospital of Chongqing Medical University
Eligibility
Sex/Gender
All
Age
18 Years to 60 Years
Inclusion criteria
Inclusion criteria: 1. Aged 18-60 years, male or female; 2. high risk MDS or AML treated by allo-HSCT and 1 month after HSCT; 3. MRD(+) after transplantation; 4. Routine blood indexes should be normal in each case; 5. Ability to understand and be willing to sign the informed consent form of this trial.
Exclusion criteria
Exclusion criteria: 1. pregnant women or lactation women; 2. patients with uncontrolled heart failure, unstable angina, arrhythmia or mental disorders; 3. uncontrolled infection disease; 4. HIV infected patients; 5. Patients with 3 or high stage chronic renal disease; 6. Relapse of MDS or AML
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| complete remission state of bone marrow;remission state of hematology ;disappear of extramedullary invasion ;event-free survival;overall survival;cumulative disease rate of relapse ; | — |
Secondary
| Measure | Time frame |
|---|---|
| early mortality rate ; | — |
Countries
China
Contacts
Public ContactLi Wang
The First Affiliated Hospital of Chongqing Medical University
Outcome results
None listed